Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$17.73 USD

17.73
1,086,085

-1.11 (-5.89%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $17.71 -0.02 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

MacroGenics (MGNX) Reports Q2 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 30.77% and 51.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for National Vision (EYE)

National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

National Vision (EYE) Gains From Store Openings Amid Cost Woes

National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.

Urmimala Biswas headshot

3 MedTech Stocks Likely to Top Estimates This Earnings Season

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.

Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of 8.70% and 95.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain National Vision (EYE) Stock Now

Investors continue to remain optimistic about National Vision (EYE) due to the expansion of stores and new investments for the improved optometric experience.

National Vision (EYE) Plans to Open New Stores Amid Macro Woes

National Vision (EYE) plans to continue executing core growth initiatives and further investing in competitive advantages.

National Vision (EYE) Q1 Earnings Top Estimates, Margins Down

National Vision's (EYE) Q1 net revenues are positively impacted by the timing of unearned revenue.

National Vision (EYE) Q1 Earnings and Revenues Beat Estimates

National Vision (EYE) delivered earnings and revenue surprises of 63.16% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of 14.63% and 3.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for National Vision (EYE) This Earnings Season?

National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Analysts Estimate National Vision (EYE) to Report a Decline in Earnings: What to Look Out for

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NanoString Technologies (NSTG) Reports Q1 Loss, Tops Revenue Estimates

NanoString (NSTG) delivered earnings and revenue surprises of -22.22% and 8.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain National Vision (EYE) Stock Now

National Vision's (EYE) share price is likely to grow following the company's efforts to expand remote capabilities and investments in doctor recruiting and retention efforts.

National Vision (EYE) Rides on Comps Growth Amid Macro Issues

National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.

EYE vs. RMD: Which Stock Should Value Investors Buy Now?

EYE vs. RMD: Which Stock Is the Better Value Option?

Should Value Investors Buy National Vision (EYE) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

National Vision (EYE) Q4 Revenues Miss Mark, Margins Down

National Vision (EYE) is facing a challenging macroeconomic environment, which negatively impacted its performance in the fourth quarter of 2022.

National Vision (EYE) Reports Q4 Loss, Misses Revenue Estimates

National Vision (EYE) delivered earnings and revenue surprises of -33.33% and 0.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zevia (ZVIA) Reports Q4 Loss, Tops Revenue Estimates

Zevia (ZVIA) delivered earnings and revenue surprises of 16.67% and 15.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 142.14% and 2.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Q4 Earnings and Revenues Miss Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of -12.24% and 1.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Investors Undervaluing National Vision (EYE) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 25.71% and 0.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates

OraSure (OSUR) delivered earnings and revenue surprises of 2,000% and 26.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?